-
11.
公开(公告)号:US20170360846A1
公开(公告)日:2017-12-21
申请号:US15619691
申请日:2017-06-12
IPC分类号: A61K35/60 , A61K31/4045 , A61K31/202 , A61K31/122 , A61K31/07 , A23L33/12 , A61J1/14 , A61K9/00 , A23L33/155 , A23L33/00 , A23P10/30 , A23L33/115 , A61K31/593 , A61K9/48
CPC分类号: A61K35/60 , A23L33/115 , A23L33/12 , A23L33/155 , A23L33/40 , A23P10/30 , A23V2002/00 , A61J1/1418 , A61K9/0053 , A61K9/48 , A61K31/07 , A61K31/122 , A61K31/202 , A61K31/4045 , A61K31/593 , A61K36/55
摘要: Disclosed is a liquid medicament/supplement composition including a non-winterized marine source oil (e.g., oil derived from fish, krill, and/or squid), a food grade or pharmaceutically acceptable form of vitamin D3 or a derivative thereof admixed in the non-winterized marine source oil, a food grade or pharmaceutically acceptable form of vitamin A or a derivative thereof admixed in the non-winterized marine source oil, optionally a food grade or pharmaceutically acceptable form of CoQ10 or a derivative thereof admixed in the non-winterized marine source oil, a food grade or pharmaceutically acceptable form of concentrated eicosapentaenoic acid and docosahexaenoic acid or ethyl ester, glyceride ester or salt of the acid and polyphenol rich vegetable oil admixed in the non-winterized marine source oil, and optionally a food grade or pharmaceutically acceptable form of melatonin or a derivative thereof admixed in the non-winterized marine source oil. The liquid medicament/supplement composition preferably has an oxidation amount measured as totox of less than 5, and the liquid medicament/supplement composition preferably has an overall eicosapentaenoic acid to docosahexaenoic acid ratio (DHA:EPA) ranging from 2:1 to 1:2 at a concentration ranging from 15 to 35 wt % of total liquid weight calculated as weight % of the corresponding free acid.
-
公开(公告)号:US20170245533A1
公开(公告)日:2017-08-31
申请号:US15445119
申请日:2017-02-28
申请人: Kyle Murphy , Frederick T Murphy
发明人: Kyle Murphy , Frederick T Murphy
IPC分类号: A23L7/196 , A23L33/15 , A23L33/16 , A23L33/155
CPC分类号: A23L7/1965 , A23L33/15 , A23L33/155 , A23L33/16 , A23V2002/00 , A23V2200/30 , A23V2250/1592 , A23V2250/1598 , A23V2250/16 , A23V2250/161 , A23V2250/1614 , A23V2250/1618 , A23V2250/1626 , A23V2250/702 , A23V2250/7042 , A23V2250/7046 , A23V2250/7052 , A23V2250/7058 , A23V2250/706 , A23V2250/708 , A23V2250/7106 , A23V2250/712
摘要: A micronutrient fortification supplement which may include one or more of the an effective amount of the following: Vitamin A; Vitamin C; Vitamin D3; Vitamin E; Vitamin B1; Vitamin B3; Vitamin B2; Vitamin B6; Vitamin B9; Vitamin B12; Iron; Zinc; Sodium; Potassium; Chloride; Magnesium; Calcium; Phosphorus; Selenium; Iodine; Fluoride; and optionally a flavoring agent, which may be enclosed in the hollow interior of a sachet and which may be in powder form for dispersing over prepared food.
-
公开(公告)号:US09744182B2
公开(公告)日:2017-08-29
申请号:US14957304
申请日:2015-12-02
申请人: Buriva, LLC
发明人: Rhett Sean Daniels , Brett B Bartel
IPC分类号: A61K31/685 , A61K31/375 , A61K31/355 , A61K31/519 , A61K31/59 , A61K31/675 , A61K31/714 , A61K33/06 , A61K33/18 , A61K33/26 , A61K31/592 , A61K31/593 , A61K31/4415 , A61K31/341 , A61K31/198 , A61K45/06 , A61K35/57 , A23P10/30 , A23P10/40 , A23L33/00 , A23L33/12 , A23L33/15 , A23L33/155 , A23L33/16
CPC分类号: A61K31/685 , A23L33/12 , A23L33/15 , A23L33/155 , A23L33/16 , A23L33/40 , A23P10/30 , A23P10/40 , A23V2002/00 , A61K31/198 , A61K31/341 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/59 , A61K31/592 , A61K31/593 , A61K31/675 , A61K31/714 , A61K33/06 , A61K33/18 , A61K33/26 , A61K35/57 , A61K45/06 , A61K2300/00 , A23V2200/30 , A23V2200/32 , A23V2250/184 , A23V2250/1868 , A23V2250/187 , A23V2250/1882
摘要: Described herein are manufactured dietary supplements that contain a phospholipid extract, folic acid, vitamin D, vitamin B6, vitamin B12, Vitamin E, Vitamin C, iodine, iron, and magnesium.Described herein are manufactured dietary supplements that contain a phospholipid extract that contain phospholipid-DHA.
-
公开(公告)号:US20170202860A1
公开(公告)日:2017-07-20
申请号:US15392730
申请日:2016-12-28
申请人: Bruce L. Howe , Kodimule Prasad
发明人: Bruce L. Howe , Kodimule Prasad
IPC分类号: A61K31/593 , A61K36/81 , A23L33/155 , A61K47/44
CPC分类号: A61K31/593 , A23D9/007 , A23K20/158 , A23K20/174 , A23L33/155 , A23V2002/00 , A61K9/0053 , A61K9/0095 , A61K31/592 , A61K36/81 , A61K47/44 , A61K2236/37 , A23V2250/194 , A23V2250/2131 , A23V2250/7104 , A23V2250/7106
摘要: The invention is directed to compositions of vitamin D having enhanced bioavailability and enhanced stability. Methods of making and using the compositions of the invention are contemplated and disclosed.
-
公开(公告)号:US09707242B2
公开(公告)日:2017-07-18
申请号:US14780299
申请日:2014-03-27
申请人: DSM IP ASSETS B.V.
发明人: Elske Maria Brouwer-Brolsma , Edith Johanna Maria Feskens , Lisette De Groot , Stephanie J. M. Krammer-Lukas , Hasan Mohajeri , Szabolcs Peter , Jonas Witter-Schegg
IPC分类号: A61K31/593 , A61K9/00 , A23L33/155
CPC分类号: A61K31/593 , A23L33/155 , A23V2002/00 , A61K9/0053 , A23V2200/322 , A23V2250/71 , A23V2250/7106 , A61K2300/00
摘要: This invention relates to the use of 25-hydroxyvitamin D3 (25-OH D3) to increase or maintain or alternatively, to lessen the decrease of the cognitive element known as executive functioning in healthy individuals. Optionally, 25-OH D3 may be administered in combination with Vitamin D or other ingredients.
-
公开(公告)号:US09707241B2
公开(公告)日:2017-07-18
申请号:US14869533
申请日:2015-09-29
发明人: John Rathmacher , John Fuller, Jr. , Shawn Baier , Steve Nissen , Naji Abumrad
IPC分类号: A61K31/19 , A61K31/59 , A23L33/00 , A23L33/175 , A23L33/15 , A23K20/174 , A23K20/00 , A61K31/593 , A23L33/155 , A23L33/10 , A61K9/00
CPC分类号: A61K31/59 , A23K20/00 , A23K20/174 , A23L33/10 , A23L33/15 , A23L33/155 , A23L33/175 , A23L33/30 , A23V2002/00 , A61K31/19 , A61K31/593 , A61K2300/00 , A23V2250/71 , A23V2200/316
摘要: The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.
-
公开(公告)号:US20170157054A1
公开(公告)日:2017-06-08
申请号:US15440630
申请日:2017-02-23
申请人: DSM IP ASSETS B.V.
发明人: Markus BECK , Hansjoerg GRASS , Bruno LEUENBERGER , Markus NOWOTNY , Christian SCHÄFER , Karl Manfred VOELKER
IPC分类号: A61K9/20 , A61K31/01 , A23L33/155 , A23K20/179 , A23L5/44 , A61K31/047 , A23K20/174
CPC分类号: A61K9/2081 , A23K20/174 , A23K20/179 , A23L5/44 , A23L33/155 , A23V2002/00 , A61K8/0241 , A61K8/31 , A61K9/2013 , A61K9/2018 , A61K9/2059 , A61K31/01 , A61K31/047 , A61K2800/52 , A61K2800/56 , A61Q19/00
摘要: The present invention relates to formulations of a pharmacological effective fat-soluble active ingredient with a high bioavailability of said fat-soluble active ingredient as well as to their manufacture and use as dietary supplement, food, feed, personal care product and/or pharmaceutical. Such formulations are those which when dissolved, dispersed or diluted in/with water have an extinction E 1/1 at a wavelength in the range of from 200 to 800 nm, preferably in the range of from 250 to 600 nm, more preferably in the range of from 250 to 500 nm, more preferably in the range of from 370 to 485 nm, of ≧380, preferably of ≧600, most preferably ≧900. In preferred embodiments of the formulations of the present invention such formulations show an extrusion loss of fat-soluble active ingredient of ≦30% when pressed to tablets.
-
公开(公告)号:US20170157042A1
公开(公告)日:2017-06-08
申请号:US15435663
申请日:2017-02-17
申请人: Exeltis USA, Inc.
发明人: Eduardo Fernandez , Charles Balzer
IPC分类号: A61K9/00 , A61K31/4415 , A61K31/714 , A61K31/519 , A61K31/375 , A61K31/593 , A61K31/355 , A61K31/455 , A61K33/18 , A61K31/14 , A61K33/26 , A61K31/202 , A23G3/36 , A23G3/40 , A23L33/15 , A23L33/155 , A23L33/16 , A23L33/00 , A61K31/07
CPC分类号: A61K9/0056 , A23G3/364 , A23G3/368 , A23G3/40 , A23L33/15 , A23L33/155 , A23L33/16 , A23L33/40 , A23V2002/00 , A61K31/07 , A61K31/14 , A61K31/202 , A61K31/215 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/455 , A61K31/519 , A61K31/59 , A61K31/593 , A61K31/714 , A61K33/18 , A61K33/26 , A61K33/42 , A23V2250/1592 , A23V2250/1598 , A23V2250/1868 , A23V2250/187 , A23V2250/304 , A23V2250/702 , A23V2250/7046 , A23V2250/7052 , A23V2250/7058 , A23V2250/706 , A23V2250/708 , A23V2250/712 , A61K2300/00
摘要: A method for treating a prenatal, pregnant or breastfeeding patient for a disease, condition or disorder that is associated with a nutritional deficiency in the patient comprising administering at least one gummy composition to a patient. The gummy composition comprises an effective amount of vitamin A, vitamin B6, vitamin B12, vitamin B9, vitamin C, vitamin D, vitamin E, vitamin B3, iodine, choline, iron, and at least one omega-3 fatty acid to treat the disease, condition or disorder in the patient that is associated with a nutritional deficiency in the patient. The gummy composition is provided in a single, homogeneous mixture which is elastic, continuous and readily soluble in aqueous media.
-
19.
公开(公告)号:US09629888B2
公开(公告)日:2017-04-25
申请号:US13582655
申请日:2011-03-07
IPC分类号: A61K36/81 , A23L33/185 , A23L33/155 , A61K9/14 , A61K47/42 , A61K47/46 , A61K36/21 , A61K36/47 , A61K38/00
CPC分类号: A61K47/42 , A23L33/155 , A23L33/185 , A23V2002/00 , A61K9/146 , A61K9/148 , A61K9/19 , A61K31/593 , A61K36/21 , A61K36/47 , A61K36/81 , A61K38/00 , A61K47/46 , A23V2250/548 , A23V2250/7106
摘要: This invention describes a novel composition of matter describing a complex comprising leaf protein and a lipophilic substance(s), along with the method of producing it. Delivery of lipid-soluble materials into the body is challenging because they are generally highly insoluble in water and very subject to oxidative degradation. The inventors have found that leaf protein—the water-soluble proteins derived from plant leaves—can efficiently form a complex with lipophilic materials. This leaf protein—lipid-soluble material complex is an effective carrier of lipophilic substances. As such, the leaf protein—lipid-soluble material complex disclosed herein can be used for the delivery of lipophilic vitamins, fatty acids, caretenoids, lipophilic drugs, and other lipophilic materials. This complex can be used to deliver lipophiles in foods, nutritional and dietary supplements, topical compositions and in pharmaceutical products.
-
公开(公告)号:US20170106005A1
公开(公告)日:2017-04-20
申请号:US15393160
申请日:2016-12-28
申请人: DSM IP ASSETS B.V.
IPC分类号: A61K31/593 , A61K9/00 , A23L33/155 , A61K9/48
CPC分类号: A61K31/593 , A23L33/155 , A23V2002/00 , A61K9/0053 , A61K9/48 , A61K2300/00
摘要: Methods for treating/preventing conditions associated with an increased level of eotaxin in a human with 25-hydroxyvitamin D3 (calcifediol) are provided. Optionally, vitamin D3 may be used together with 25-hydroxyvitamin D3.
-
-
-
-
-
-
-
-
-